These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35199566)

  • 1. NCAPG is a prognostic biomarker of immune infiltration in non-small-cell lung cancer.
    Zhou Y; Fan Y; Mao Y; Lou M; Liu X; Yuan K; Tong J
    Biomark Med; 2022 May; 16(7):523-535. PubMed ID: 35199566
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of TIMELESS and RORA as key clock molecules of non-small cell lung cancer and the comprehensive analysis.
    Xian H; Li Y; Zou B; Chen Y; Yin H; Li X; Pan Y
    BMC Cancer; 2022 Jan; 22(1):107. PubMed ID: 35078435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of ALOX5 in non-small cell lung cancer: A potential therapeutic target associated with immune cell infiltration.
    Zhao Q; Sun Z; Pan Y; Jing Q; Li W; Wang C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):311-322. PubMed ID: 37164914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers.
    Usó M; Jantus-Lewintre E; Bremnes RM; Calabuig S; Blasco A; Pastor E; Borreda I; Molina-Pinelo S; Paz-Ares L; Guijarro R; Martorell M; Forteza J; Camps C; Sirera R
    Oncotarget; 2016 Aug; 7(33):52849-52861. PubMed ID: 27463005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APE1 may influence CD4+ naïve T cells on recurrence free survival in early stage NSCLC.
    Li Y; Zhao X; Xiao H; Yang B; Liu J; Rao W; Dai X; Li M; Dai N; Yang Y; Wang D
    BMC Cancer; 2021 Mar; 21(1):233. PubMed ID: 33676448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NCAPG promotes the oncogenesis and progression of non-small cell lung cancer cells through upregulating LGALS1 expression.
    Sun H; Zhang H; Yan Y; Li Y; Che G; Zhou C; Nicot C; Ma H
    Mol Cancer; 2022 Feb; 21(1):55. PubMed ID: 35180865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
    Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
    Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
    Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene co-expression modules integrated with immunoscore predicts survival of non-small cell lung cancer.
    Li XT; Zhang JT; Yan HH; Su J; Cheng ML; Sun QH; Zhong WZ; Wu YL; Zhang DX; Hou DJ
    Cancer Treat Res Commun; 2021; 26():100297. PubMed ID: 33385734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPM1D overexpression predicts poor prognosis in non-small cell lung cancer.
    Yang H; Gao XY; Li P; Jiang TS
    Tumour Biol; 2015 Mar; 36(3):2179-84. PubMed ID: 25412952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
    Zhang X; Shi X; Zhao H; Jia X; Yang Y
    Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
    Guo L; Li X; Liu R; Chen Y; Ren C; Du S
    Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A signature of tumor immune microenvironment genes associated with the prognosis of non‑small cell lung cancer.
    Li J; Li X; Zhang C; Zhang C; Wang H
    Oncol Rep; 2020 Mar; 43(3):795-806. PubMed ID: 32020214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
    Wang W; Ren S; Wang Z; Zhang C; Huang J
    Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased expression of SOX4 is a biomarker for malignant status and poor prognosis in patients with non-small cell lung cancer.
    Wang D; Hao T; Pan Y; Qian X; Zhou D
    Mol Cell Biochem; 2015 Apr; 402(1-2):75-82. PubMed ID: 25567207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NCAPG as a Novel Prognostic Biomarker in Glioma.
    Jiang X; Shi Y; Chen X; Xu H; Liu B; Zhou F; Huang X; Cho WC; Li L; Pu J
    Front Oncol; 2022; 12():831438. PubMed ID: 35280743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
    Li B; Cui Y; Diehn M; Li R
    JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioinformatics analysis and experimental validation of TTK as a biomarker for prognosis in non-small cell lung cancer.
    Chen J; Wu R; Xuan Y; Jiang M; Zeng Y
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32969465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NCAPG is a prognostic biomarker associated with vascular invasion in hepatocellular carcinoma.
    Guo ZY; Zhu ZT
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7238-7251. PubMed ID: 34919223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LETM1 is a potential biomarker of prognosis in lung non-small cell carcinoma.
    Piao L; Yang Z; Feng Y; Zhang C; Cui C; Xuan Y
    BMC Cancer; 2019 Sep; 19(1):898. PubMed ID: 31500591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.